Best peptides for growth hormone: Frequently asked questions

Ipamorelin is the only peptide that maintains >85% potency beyond 16 weeks of continuous daily administration. GHRP-2 shows moderate attenuation (15–20% reduction) by week 12, and hexarelin becomes nearly inactive by week 4. CJC-1295 with DAC doesn't desensitize but suppresses endogenous pulsatility for the entire duration. If the protocol exceeds 12 weeks and endogenous GH dynamics must remain intact, ipamorelin is the only viable option.

Hexarelin produces the highest-amplitude GH release among all peptide secretagogues. 15–25 ng/mL peaks at 2 mcg/kg dosing. However, this comes at the cost of rapid receptor desensitization, which limits protocol duration to 2–4 weeks. If the research question involves measuring peak GH capacity or downstream signaling during supra-physiological GH exposure, hexarelin is the appropriate tool. But only in short-term studies where receptor attenuation won't confound the data.

Avoid MK-677. Its 24-hour ghrelin receptor occupancy increases fasting glucose by 8-12 mg/dL in insulin-resistant individuals, likely through glucagon stimulation and hepatic glucose output. Ipamorelin or hexarelin paired with metformin or berberine represents a safer approach. Both compounds produce GH release without sustained ghrelin signaling, and metformin counteracts the modest insulin resistance that high-dose GH can induce. A 2021 study in Diabetes Care found that co-administration of 500 mg metformin with ipamorelin protocols prevented the 6-8% increase in fasting glucose observed with MK-677 alone.

Use ipamorelin or CJC-1295 without DAC. Both produce discrete pulses that preserve the body's endogenous secretory pattern. Ipamorelin peaks within 20 minutes and clears within 90 minutes, while CJC-1295 (no DAC) extends the pulse duration slightly without suppressing inter-pulse intervals. CJC-1295 with DAC is inappropriate for this scenario because its sustained albumin-bound presence flattens circadian variation entirely, suppressing the nocturnal GH surge that occurs during slow-wave sleep.

These are expected effects of elevated GH. Growth hormone increases sodium retention via the kidneys and stimulates extracellular fluid expansion. Reducing dosage from 25 mg to 12.5 mg daily typically alleviates symptoms while maintaining 60–70% of the IGF-1 increase. Joint discomfort usually resolves within 2–3 weeks as connective tissues adapt to increased collagen synthesis. If symptoms persist beyond 4 weeks, discontinue MK-677 and switch to injectable peptides with shorter half-lives.

Use the combination. CJC-1295 alone extends the duration of GHRH signaling but doesn't increase pulse amplitude. It raises baseline GH secretion modestly. Ipamorelin adds peak amplitude by triggering GH release through ghrelin receptors, which means the combined effect is both higher baseline and sharper pulses. Research protocols using both together show 2–3× the IGF-1 increase compared to either peptide alone.

Stack hexarelin (100 mcg) with MOD-GRF 1-29 (100 mcg) administered 15 minutes before the target measurement window. This combination exploits full receptor synergy without the prolonged occupancy of long-acting analogs. Research from the Journal of Clinical Endocrinology documented GH peaks exceeding 50 ng/mL within 20-30 minutes of co-administration, a response magnitude unattainable with rhGH injections. This protocol is used in provocative GH testing and research models requiring maximal acute secretion rather than sustained elevation.

Use CJC-1295 with DAC as the base compound. Its 6-8 day half-life allows twice-weekly dosing while maintaining IGF-1 elevation throughout the study period. Research conducted at the University of Virginia demonstrated that 60 mcg/kg CJC-1295 administered every 7 days produced sustained IGF-1 increases of 40-60% above baseline for the entire inter-dose interval. This eliminates the compliance challenges of daily peptide reconstitution and injection timing. The trade-off: you lose the ability to time doses around specific anabolic windows like post-exercise or sleep onset, which matters if the research protocol targets acute GH pulses rather than chronic IGF-1 elevation.

First, verify peptide reconstitution and storage. Improperly stored peptides (above 8°C for more than 48 hours) lose potency irreversibly. Second, confirm injection timing. Administering peptides immediately after meals blunts GH release due to elevated glucose and insulin. Third, check dosage accuracy using an insulin syringe with 0.01 mL graduations. If all three are correct and IGF-1 remains unchanged, the issue is likely pituitary insufficiency rather than hypothalamic. Meaning ghrelin agonists may be ineffective, and GHRH analogues are addressing a problem downstream of where the failure actually occurs.

Switch to CJC-1295 with DAC, which has a 6–8 day half-life and sustains GH elevation with once-weekly subcutaneous administration. Pair it with a once-daily ghrelin agonist like MK-677, an orally active GHS-R1a agonist with a 4–6 hour half-life that produces GH pulses 90–120 minutes post-dose. This combination maintains elevated GH without requiring multiple daily injections.

This is expected. Hexarelin binds CD36 scavenger receptors in cardiac and other tissues, leading to receptor desensitization with chronic administration. Studies show blunted GH response by week 16 of daily hexarelin use, returning near baseline despite continued dosing. Switch to ipamorelin or rotate peptides using 4-week on / 2-week off cycles to prevent desensitization. Ipamorelin does not bind CD36 and maintains GH response over 24+ week protocols.

Use ipamorelin as a monotherapy or stacked with CJC-1295. Ipamorelin is the most selective GHS-R1a agonist available. It produces 13-fold GH increases without detectable cortisol, prolactin, or ACTH elevation at standard research doses. GHRP-2 and hexarelin both trigger cortisol spillover that confounds metabolic and stress-response studies.

Discard it immediately. Cloudiness or visible particles indicate protein aggregation or contamination. Properly reconstituted peptides should be clear and colorless. Aggregated peptide loses bioactivity and may trigger immune responses in research models. Store lyophilized peptides at −20°C before reconstitution; once mixed with bacteriostatic water, refrigerate at 2–8°C and use within 28 days.